The European Code Against Cancer (ECAC) recommends that if you drink alcohol of any type you should limit your intake and that not drinking alcohol is best for cancer prevention.
This March, the PrEvCan campaign, spearheaded by EONS to promote cancer prevention across Europe, is bringing attention to the link between alcohol consumption and cancer risk. In this interview, cancer nurse and leader of the EONS advocacy working group, Helena Ullgren, discusses the scientific evidence supporting this connection. We then explore ways that healthcare professionals can better enhance public awareness about this risk and effectively communicate the significance of cancer prevention. Furthermore, we explore various resources that can assist individuals in reducing their alcohol consumption.
- Could you give us a brief overview of the PrEvCan campaign? (0:26)
- What evidence shows that drinking alcohol can increase cancer risk? (2:31)
- In which cancers is there strongest evidence of risk? (3:11)
- What are the recommendations of ECAC in terms of alcohol? (3:39)
- What resources are available to help people limit their alcohol intake? (4:19)
Disclosures: Helena Ullgren has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Learn more about the PrEvCan campaign, and download toolkits and videos to help you spread the PrEvCan messages here: https://cancernurse.eu/prevcan/
Share this Video
Related Videos In Policy
Raising awareness around HPV infection, cancer risk and vaccination: PrEvCan | Daniel Kelly
The PrEvCan – Cancer Prevention Across Europe – campaign, initiated by the European Oncology Nursing Society (EONS) and supported by ESMO, aims to reduce the burden of cancer by promoting a different way we can decrease cancer risk each month. This August, the PrEvCan campaign focuses on raising awareness about the connection between human papillomavirus […]
Vivek Subbiah, AACR 2023: The purpose of phase I clinical trials
The purpose of phase I clinical trials are to evaluate the safety, dosage and potential side effects of a new drug or treatment in humans for the first time. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) to discuss the purpose and details […]
Vivek Subbiah, AACR 2023: The evolution of phase I clinical trials in the era of precision medicine
Precision medicine aims to tailor medical treatments to individual patients based on their characteristics and genetic makeup. Phase I clinical trials are seeing changes in their objectives and designs in the era of precision medicine. In this touchONCOLOGY interview, we speak with Dr Vivek Subbiah (University of Texas, MD Anderson Cancer Centre, Houston, TX, USA) […]